News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Introgen and Collaborators at M. D. Anderson Cancer Center Demonstrate Systemic Delivery With Improved Non-Viral System (PR Newswire)...``Successful Treatment of Primary and Disseminated Human Lung Cancers by Systemic Delivery of Tumor Suppressor Genes Using an Improved Liposome Vector`` conducted at the M. D. Anderson Cancer Center,......Liposomal complexes of the tumor suppressor genes were tested for their ability to induce anti-tumor effects when administered intratumorally by injection into primary tumors, and by intravenous injection into models of metatstatic disease.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....- Apr 17 7:30 AM ET


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010417/datu023.html


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740